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Report
Untreated Congenital Adrenal Hyperplasia with 17-α 
Hydroxylase/17,20-Lyase Deficiency Presenting as 
Massive Adrenocortical Tumor 
Su Jin Lee, Je Eun Song, Sena Hwang, Ji-Yeon Lee, Hye-Sun Park, Seunghee Han, Yumie Rhee
Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea 
Congenital adrenal hyperplasia (CAH) with 17α-hydroxylase/17,20-lyase deficiency is usually characterized by hypertension and 
primary amenorrhea, sexual infantilism in women, and pseudohermaphroditism in men. hypertension, and sexual infantilism in 
women and pseudohermaphroditism in men. In rare cases, a huge adrenal gland tumor can present as a clinical manifestation in 
untreated CAH. Adrenal cortical adenoma is an even more rare phenotype in CAH with 17α-hydroxylase/17,20-lyase deficiency. 
A 36-year-old female presented with hypertension and abdominal pain caused by a huge adrenal mass. Due to mass size and 
symptoms, left adrenalectomy was performed. After adrenalectomy, blood pressure remained high. Based on hormonal and ge-
netic evaluation, the patient was diagnosed as CAH with 17α-hydroxylase/17,20-lyase deficiency. The possibility of a tumorous 
change in the adrenal gland due to untreated CAH should be considered. It is important that untreated CAH not be misdiagnosed 
as primary adrenal tumor as these conditions require different treatments. Adequate suppression of adrenocorticotropic hormone 
(ACTH) in CAH is also important to treat and to prevent the tumorous changes in the adrenal gland. Herein, we report a case of 
untreated CAH with 17α-hydroxylase/17,20-lyase deficiency presenting with large adrenal cortical adenoma and discuss the pro-
gression of adrenal gland hyperplasia due to inappropriate suppression of ACTH secretion. 
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INTRODUCTION
Congenital adrenal hyperplasia (CAH) is an autosomal reces-
sive disease caused by various genetic defects of the enzyme in-
volved in cortisol biosynthesis in the adrenal glands and ranges 
from mild to severe according to the degree of enzyme dysfunc-
tion [1]. Twenty-one-hydroxylase deficiency, occurring in 1 of 
16,000 births [1], is the most frequent type of CAH. However, 
17α-hydroxylase/17,20-lyase deficiency of CAH is very rare 
[2]. Loss-of-function mutation of CYP17A1 gene, which nor-
mally activates 17α-hydroxylase/17,20-lyase, can result in de-
fective P450c17 action and present as primary amenorrhea and 
abnormality of secondary sex characteristics in women and as 
pseudohermaphroditism in men. The deterioration producing 
cortisol in the adrenal cortex stimulates adrenocorticotropic hor-
mone (ACTH) secretion in the pituitary gland, leading to hyper-
plasia of the adrenal cortex. Long-term overproduction of 
ACTH due to inadequately treated or untreated CAH rarely 
transforms to adrenal cortical adenoma or carcinoma [3-6]. 
Herein, we present a case of a huge adrenal mass confirmed as 
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adrenal cortical adenoma in CAH with 17α hydroxylase/17,20-
lyase deficiency. 
CASE REPORT
A 36-year-old female visited the emergency department with 
pain in the left upper abdominal quadrant. She brought her ab-
dominal computed tomography (CT) scan taken in another hos-
pital showing a 10×6.3×8.6 cm-sized left adrenal mass with 
hemorrhagic necrosis (Fig. 1A). On admission, her systolic 
blood pressure was 150 to 170 mm Hg and her diastolic blood 
pressure was 100 to 110 mm Hg, higher than the standard val-
ues for her age. She had no previous history of hypertension. 
Her weight was 63 kg, and her height was 175 cm. The routine 
biochemical study, random urine analysis, and blood coagula-
tion test results were all normal, and the serum electrolytes 
showed Na 141 mmol/L (normal range [NR], 135 to 145), K 3.3 
mmol/L (NR, 3.5 to 5.5), and Cl 100 mmol/L (NR, 98 to 120). 
Hormone tests showed cortisol was reduced to 0.9 μg/dL (NR, 
6.7 to 22.6) and ACTH was elevated slightly, to 75.94 pg/mL 
(NR, 7.2 to 63.6). Renin was reduced to 0.80 ng/mL/hr (NR, 
1.31 to 3.95) and aldosterone was elevated to 183.31 pg/mL 
(NR, 29.9 to 158.8). The aldosterone renin ratio was 22.9. Chest 
X-ray and electrocardiography were normal. The results of 24-
hour urine analysis were as follows: metanephrine 0.518 mg/
day (NR, 0 to 1.3), epinephrine 2.3 μg/day (NR, 0 to 20), and 
vanillylmandelic acid 4.04 mg/day (NR, 0 to 8); all values were 
within the NR except those for 17-ketosteroids 2.77 mg/day 
(NR, 7 to 20) and urinary free cortisol 37.6 (NR, 55.5 to 286). 
Typical CT findings of a large adrenal mass with hemorrhagic 
necrosis led to the diagnosis of pheochromocytoma with bio-
chemically burnt-out status.
 To further evaluate the characteristics of the adrenal mass, 
metaiodobenzylguanidine-single-photon emission computed to-
mography (MIBG-SPECT) imaging was performed and showed 
no significant radiotracer uptake. Next, 18F-fluorodeoxyglucose 
positron emission tomography-CT (18F-FDG PET-CT) was per-
formed, and the FDG uptake in the solid portion of the mass 
was elevated (Fig. 1B). On CT scan, the contralateral right adre-
nal gland appeared relatively normal. The possibility of pheo-
chromocytoma could not be excluded based on MIBG-negative 
and PET-positive findings. Thus, after proper premedication, the 
mass was surgically removed due its size. After laparoscopic 
adrenalectomy, a left hemorrhagic adrenal mass was pathologi-
cally confirmed as adrenal cortical adenoma 10×5×3 cm in 
size (Fig. 2). The patient complained of nausea and generalized 
weakness after the left adrenalectomy. Moreover, blood pressure 
remained at 190/119 mm Hg. After the operation, her ACTH 
was elevated to 406.9 pg/mL (NR, 7.2 to 63.6), and the low-
dose ACTH stimulation test showed her cortisol was 1.0 μg/dL 
(NR, 6.7 to 22.6) at baseline, 1.6 μg/dL after 30 minutes, and 1.0 
μg/dL after 1 hour showing blunted response. After reviewing 
her abdominal CT, we discovered that she had received plastic 
surgery on both breasts. We requested the patient regarding her 
medical history as she had failed to mention this procedure on 
the first visit. The patient had artificial prostheses inserted be-
Fig. 1. (A) Computed tomography (CT) scan of the large, 7.6-cm, hemorrhagic mass in the left adrenal gland (white arrows). (B) Fluoro-
deoxyglucose (FDG) uptake (black arrow) in the solid portion of the mass in 18F-FDG-positron emission tomography-CT.
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cause she never developed breasts during puberty. She also 
lacked secondary sexual characteristics such as pubic and axil-
lary hair (Tanner stage I). The patient confessed she experienced 
no menarche in puberty and had kept these facts secret even 
from her family members. Further hormone testing showed the 
followings: thyroid stimulating hormone 3.1 μIU/mL (NR, 0.4 
to 4.9), prolactin 27.2 ng/mL (NR, 3.3 to 26.7), luteininzing hor-
mone 25.0 mIU/mL (NR, 1.2 to 10.9), follicular stimulating 
hormone 51.5 mIU/mL (NR, 1.8 to 8.8), estradiol <20 pg/mL 
(NR, 27 to 433), progesterone 4.32 ng/mL (NR, 0.2 to 23), and 
17-OH-progesterone 0.21 ng/mL (NR, 0.1 to 5.0). However, 
both dehydroepiandrosterone (DHEA) and renin were reduced 
to 0.41 μg/mL (NR, 1.3 to 9.8) and 0.7 ng/mL/hr (NR, 1.3 to 
3.9), respectively, whereas aldosterone was elevated to 171.9 
pg/mL (NR, 29.9 to 158.8) (Table 1). Furthermore, X-ray exam-
ination of the upper arm showed that the bone age was compati-
ble with that of a 15-year-old female and bone mineral density 
Fig. 2. Gross finding of adrenal cortical adenoma with degenera-
tive cystic change.
Table 1. Comparison of Hormone Levels before and after Left 
Adrenalectomy
Hormone Before surgery
After 
surgery
Reference 
range 
Cortisol, μg/dL 0.9 1 6.7–22.6 
ACTH, pg/mL 75.94 406.9 7.2–63.6
Aldosterone, pg/m L 183.31 169.98 29.9–158.8
Renin, ng/mL/hr 0.8 0.46 1.31–3.95
DHEA, μg/mL - 0.7 1.3–9.8
Progesterone, ng/mL - 4.32 0.15–23
17-OH-progesterone, ng/mL - 0.21 0.11–5.0 
Estradiol, pg/mL - <20 27–433
Testosterone, ng/dL - <2.5 8.4–48.1
FSH, mIU/mL - 51.5 1.79–8.78
LH, mIU/mL - 25.01 1.20–10.89
TSH, μIU/mL - 3.13 0.35–4.94 
Prolactin, ng/mL - 27.2 3.34–26.72 
ACTH, adrenocorticotropic hormone; DHEA, dehydroepiandros-
terone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; 
TSH, thyroid-stimulating hormone.
Fig. 3. Computed tomography scan of the right adrenal gland after adrenalectomy (white arrows). (A) Hyperplasia in right adrenal gland 
immediately after left adrenalectomy. (B) Progression of hyperplasia in right adrenal gland after 3-year follow-up due to poor compliance.
Immediately after surgery 3-Year after surgery
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was below the expected range for her actual age (Z-score –3.1 
in the lumbar spine and Z-score –3.4 in the femoral neck), prob-
ably due to sex hormone deficiency. Chromosomal study of the 
patient was performed using peripheral blood leukocytes and 
showed a normal karyotype of 46, XX, female. We also con-
ducted polymerase chain reaction for all intron sequences in the 
neighborhood of the CYP17A1 gene using appropriate primers. 
According to mutation analysis, we found a compound hetero-
zygous mutation for p.Tyr329fs (c.985_987delTACinsAA) and 
missense mutation p.His373Leu (c.1118A>T) in exon 6. She 
was diagnosed with CAH caused by 17α-hydroxylase/17,20-
lyase deficiency confirmed by the CYP17A1 gene mutation, 
presenting with lack of secondary sexual development, reduced 
production of cortisol and DHEA, increased aldosterone and 
ACTH as well as atypical huge adrenal mass. The patient was 
started on oral prednisolone, 7.5 mg in the morning and 5 mg in 
the afternoon, combined with estrogen. Finally, general weak-
ness improved significantly, and the dose of oral prednisolone 
was reduced to 5 mg in the morning and 2.5 mg in the after-
noon. To date, her hormone level has been monitored for 3 
years. Due to her poor compliance and concerns of weight gain 
(although only 5 mg of prednisolone was prescribed), ACTH re-
mained high. Inadequate suppression of ACTH resulted in the 
progression of hyperplasia of the right adrenal gland observed 
on the 3-year follow-up CT scan (Fig. 3). 
DISCUSSION
CAH is characterized by adrenal enlargement resulting from ex-
cessive ACTH due to defective steroidogenesis. However, neo-
plastic transformation of the adrenal gland, such as adrenal cor-
tical adenoma is a rare complication in CAH. Shimshi et al. [7] 
reported on a 51-year-old female with a 7-cm virilizing adreno-
cortical tumor in CAH due to 21-hydroxylase deficiency after 
reviewing nine cases including six adrenal adenomas and three 
carcinomas. Other studies reported adrenal masses diagnosed as 
adrenal cortical adenoma due to 21-hydroxylase deficiency [3-
5,7-11]. Kacem et al. [10] also reported on a 22-year-old patient 
with 11β-hydroxylase deficiency having a 16-cm-sized adrenal 
cystic mass. To date, most adrenal cortical adenomas or carcino-
mas reported in CAH have been due to 21-hydroxylase defi-
ciency, and very few have been caused by 11β-hydroxylase or 
3β-hydroxysteroid dehydrogenase deficiencies [12]. Although 
adrenal myelolipoma associated with CAH has been reported 
[13], reports on 17α-hydroxylase/17,20-lyase deficiency with a 
huge adrenal adenoma and degenerative cystic change in a patient 
have not yet been published.
 The case in the present study involved CAH with 17α- 
hydroxylase/17,20-lyase deficiency and a compound heterozy-
gotic gene mutation of p.Tyr329lysfs (c.985_987delTACinsAA) 
and p.His373Leu (c.1118A>T) at different sites on the same 
exon (exon 6), indicating that each mutation exists in different 
allelic genes as a heterozygote type. Cytochrome P450 17α- 
hydroxylase enzyme, an important enzyme involved in cortisol 
biosynthesis, is encoded by the CYP17A1, gene and 17α- 
hydroxylase/17,20-lyase deficiency is caused by a mutation in 
the CYP17A1 gene, which was first reported by Biglieri et al. 
[14] in a single patient [15]. CYP17A1 gene mutation resulting 
in 17α-hydroxylase/17,20-lyase deficiency deteriorates the syn-
thesis of cortisol, testosterone, and estrogen, leading to the stim-
ulation of ACTH and gonadotrophin hormone manifesting as 
hypergonadotropic hypogonadism, with accompanying over-
production of mineralocorticoids. Excessive mineralocorticoids 
may increase blood pressure or result in hypokalemia, as in this 
case. Moreover, due to the sex hormone deficiency, a patient 
with chromosome 46,XX will not experience secondary sex de-
velopment and menstruation, whereas a patient with 46,XY will 
show female external genitalia [16,17]. Primary amenorrhea, 
lack of secondary sexual development, and hypertension are the 
usual clinical presentations of 17α-hydroxylase/17,20-lyase de-
ficiency. Atypically, the patient in this case came to the hospital 
at a comparatively old age complaining abdominal pain caused 
by the huge adrenal mass that had been suspected to be pheo-
chromocytoma in the early stage, and this clinical manifestation 
was not the typical pattern compared with other CAH cases 
with 17α-hydroxylase/17,20-lyase deficiency. Kim et al. [18] re-
viewed the CYP17A1 mutations in adults with 17α-hydroxylase 
/17,20-lyase deficiency in Korea; however, clinical presentation 
of adrenal cortical adenoma in a patient has not been reported. 
 Adrenal enlargement and neoplastic change could be due to 
inadequate glucocorticoid treatment or non-treatment. Falke et 
al. [4] reviewed CT images in 13 cases of CAH according to 
the glucocorticosteroid treatment. Of the patients, seven who 
were treated properly showed no adrenal mass, but six, who 
were not treated properly showed gross enlargement of the ad-
renals. In our case, the patient had not been treated until her 
first visit at the age of 36; thus, the over 30-year continuous 
ACTH stimulation due to cortisol and sex hormone defects 
caused by 17α-hydroxylase/17,20-lyase deficiency led to the 
large adrenal adenoma. Whether the adrenal tumor was the re-
sult of long-term overstimulation of ACTH remains question-
able. However, a correlation between adrenal hyperplasia and 
Lee SJ, et al.
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high ACTH levels is plausible given previous reports that ade-
quate treatment that suppresses ACTH hypersecretion can re-
verse the adrenal enlargement [4,6].
 Additionally, unlike the other cases of 17α-hydroxylase/ 
17,20-lyase deficiency, the aldosterone level was high in our pa-
tient [14]. Yamakita et al. [19] suggested the severity of 
17α-hydroxylase/17,20-lyase deficiency would be associated 
with the potency of cytochrome P450 corticosterone methyloxi-
dase (aldosterone synthase), a key enzyme in the conversion of 
corticosterone to aldosterone. In severe 17α-hydroxylase/17,20-
lyase deficiency, aldosterone synthase activity is more potenti-
ated in outer zona fasciculata cells, leading to increased aldo-
sterone. Furthermore, chronically elevated ACTH may have af-
fected the production of aldosterone in zona glomerulosa, 
which is also responsive to ACTH [19,20]. Of the three CAH 
cases with 17α-hydroxylase/17,20-lyase deficiency and a com-
pound heterozygote gene mutation reported by Kim et al. [18], 
one patient with a high aldosterone level presented with higher 
blood pressure and ACTH level and lower cortisol (similar to 
our case) compared with the other two cases. Further studies of 
hyperaldosteronism-related phenotypes are necessary to ex-
plain the elevated aldosterone levels. 
 In conclusion, it is rare for CAH to manifest as adrenal corti-
cal adenoma. Moreover, no huge adrenocortical adenoma has 
been reported in CAH with 17-α hydroxylase/17,20-lyase defi-
ciency. In our case, a huge adrenal mass was initially consid-
ered a pheochromocytoma. Primary amenorrhea in female pa-
tients who present with both sexual infantilism and mineralo-
corticoid hypertension should be the focus of differential diag-
nosis. Additionally, proper glucocorticoid replacement is im-
portant for preventing adrenal gland enlargement or reducing 
the possibility of transformation into a tumor. 
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